Fulcrum Therapeutics (FULC) Change in Account Payables (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Change in Account Payables of $975000.0 for Q2 2026, up 299.59% year-over-year from $244000.0 in Q2 2025, and up 13.64% quarter-over-quarter from $858000.0 in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Change in Account Payables (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Change in Account Payables for 9 consecutive years, with $975000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Account Payables rose 299.59% year-over-year to $975000.0; the TTM figure through Jun 2026 stood at $1.7 million (up 192.33% YoY), while the FY2025 annual figure was $428000.0, up 126.87% from the prior year.
- Change in Account Payables advanced to $975000.0 in Q2 2026 per FULC's latest filing, from $858000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.1 million in Q1 2024 and bottomed at -$2.7 million in Q4 2024.
- Historically, Change in Account Payables has averaged -$75611.1 across 5 years, with a median of $203500.0 in 2023.
- On a YoY basis, Change in Account Payables climbed as much as 1150.0% in 2024 and fell as far as 279.75% in 2024.
- Fulcrum Therapeutics' Change in Account Payables stood at $903000.0 in 2022, then sank by 190.48% to -$817000.0 in 2023, then slumped by 230.11% to -$2.7 million in 2024, then surged by 59.03% to -$1.1 million in 2025, then soared by 188.24% to $975000.0 in 2026.
- Business Quant data shows FULC's Change in Account Payables at $975000.0 in Q2 2026, $858000.0 in Q1 2026, and -$1.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | 975,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 975,000.00 |
| Mar 31, 2026 | 858,000.00 |
| Dec 31, 2025 | -1.11 Mn |
| Sep 30, 2025 | 946,000.00 |
| Jun 30, 2025 | 244,000.00 |
| Mar 31, 2025 | 343,000.00 |
| Dec 31, 2024 | -2.70 Mn |
| Sep 30, 2024 | 297,000.00 |
| Jun 30, 2024 | -293,000.00 |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | -817,000.00 |
| Sep 30, 2023 | -287,000.00 |
| Jun 30, 2023 | 163,000.00 |
| Mar 31, 2023 | 88,000.00 |
| Dec 31, 2022 | 903,000.00 |
| Sep 30, 2022 | -2.55 Mn |
| Jun 30, 2022 | -38,000.00 |
| Mar 31, 2022 | 509,000.00 |
| Dec 31, 2021 | 1.18 Mn |
| Sep 30, 2021 | -825,000.00 |